Wednesday, 18 November 2026 Tracking Indian retail every day
Healthcare

Biocon wins EU nod for breast cancer biosimilar Pebrilzo

The European Commission has cleared Biocon's pertuzumab biosimilar, the first approval under the EU's new tailored clinical pathway, giving the company a fifth oncology biosimilar in both Europe and the US.

Biocon wins EU nod for breast cancer biosimilar Pebrilzo

The short answer

Biocon has received European Commission approval for Pebrilzo, its pertuzumab biosimilar for HER2-positive breast cancer. Biocon CEO Shreehas Tambe is quoted saying it is the first approval under the EU's new tailored clinical pathway, and that pertuzumab is now the company's fifth oncology biosimilar cleared in both Europe and the US.

Key takeaways

  • Biocon has received European Commission approval for Pebrilzo, its pertuzumab biosimilar for HER2-positive breast cancer.
  • Biocon CEO Shreehas Tambe is quoted saying the approval is the first under the EU's new tailored clinical pathway.
  • Pebrilzo is Biocon's fifth oncology biosimilar approved in both Europe and the US, according to CEO Shreehas Tambe.
  • The sources reviewed do not mention EU launch timing, pricing or partner arrangements for the product.

Biocon has secured European Commission approval for Pebrilzo, its biosimilar version of pertuzumab, for HER2-positive breast cancer across several stages of the disease in the European Union. Biocon CEO Shreehas Tambe is quoted saying the clearance is the first granted under what the company calls the European Commission's new tailored clinical pathway, which he described as a significant milestone.

Pebrilzo is cleared for use alongside trastuzumab and chemotherapy to treat adults before surgery who have HER2-positive breast cancer that is locally advanced, inflammatory or early-stage and carries a high risk of recurrence. A second indication covers adults with HER2-positive early breast cancer at high risk of recurrence, for treatment after surgery. Those claims are the regulator's and the company's, not ours.

Shreehas Tambe, Biocon's chief executive and managing director, said the approval makes pertuzumab the company's fifth oncology biosimilar cleared in both Europe and the US, and that it strengthens the global oncology portfolio.

What is a tailored clinical pathway and why does it matter?

A biosimilar is a follow-on version of a biologic medicine whose patent has expired. Regulators require makers to show it is highly similar to the original in quality, safety and efficacy, rather than repeating full clinical trials from scratch.

Biocon describes the tailored clinical pathway as a new regulatory route; the sources reviewed do not detail what it entails. For a company like Biocon, the value sits less in the science headline and more in the cost and speed of getting to market. A lighter clinical dossier can mean fewer trial sites, shorter timelines and lower spend per asset. The approval being the first of its kind shows the pathway is now usable in practice, which matters for Biocon's remaining pipeline and for any Indian peer weighing the same route.

Where does this leave Biocon's oncology pipeline?

Biocon's oncology portfolio spans treatments for solid tumours, breast cancer among them, as well as supportive care for neutropenia caused by chemotherapy. Getting a fifth oncology biosimilar into both Europe and the US matters because these are the two markets where biosimilar pricing, tender access and payer acceptance are hardest to win and most valuable to hold.

The sources reviewed do not mention launch timing, pricing or partner arrangements for Pebrilzo in the EU. Until such details emerge, the commercial value of this approval is hard to size.

  • Portfolio depth: five oncology biosimilars cleared in Europe and the US, by the company's count.
  • Regulatory precedent: first approval under the EU's tailored clinical pathway, per the CEO.
  • Unconfirmed: EU launch date, pricing and distribution arrangements.

What does this mean for Indian pharma's biosimilar export strategy?

Indian drugmakers have built a large generics export business. Biosimilars are the next step up: harder to make, harder to approve, and priced higher than small-molecule generics. Europe is the prize because it is a regulated market with a defined biosimilar approval route and public procurement that rewards early entrants.

For founders and investors tracking Indian pharma, the signal here is about repeatability. One approval can be luck and persistence. Five oncology biosimilars cleared in both Europe and the US suggests a regulatory machine that can be fed new assets. If the tailored pathway shortens the evidence package for future filings, the economics of each incremental biosimilar improve.

The approval is a regulatory milestone, not a revenue event. The revenue comes when European payers and hospitals start buying.

There is a trade-off. Europe's biosimilar market is price competitive, and hospital tenders can compress margins quickly once several versions of the same molecule are approved. Being first in the tailored pathway helps with speed; it does not guarantee share.

What to watch next

  1. Biocon's disclosure on EU launch timing and pricing for Pebrilzo.
  2. Whether European regulators grant more approvals under the tailored clinical pathway, and which Indian companies use it.
  3. How quickly European payers and hospitals add pertuzumab biosimilars to formularies and tenders.
  4. Any further oncology biosimilar filings from Biocon as it builds on the fifth approval.

Frequently asked questions

What is Biocon's breast cancer biosimilar Pebrilzo?

Pebrilzo is Biocon's biosimilar version of pertuzumab, approved by the European Commission for HER2-positive breast cancer at multiple stages. It is used with trastuzumab and chemotherapy before and after surgery for adults at high risk of recurrence.

What is the European Commission's tailored clinical pathway?

Biocon describes it as a new tailored clinical pathway; the sources reviewed do not detail what it entails. Biocon CEO Shreehas Tambe is quoted saying Pebrilzo is the first product approved under it.

How many oncology biosimilars does Biocon have approved in Europe and the US?

With pertuzumab, Biocon says it has five oncology biosimilars approved in both Europe and the US. Its oncology portfolio spans treatments for solid tumours, breast cancer among them, as well as supportive care for neutropenia caused by chemotherapy.

Has Biocon announced pricing or a launch date for Pebrilzo in Europe?

The sources reviewed do not mention pricing or launch timing for Pebrilzo in Europe, so the commercial impact of the approval is not yet known.

Based on company announcements, filings and reporting by ET Pharma and BusinessLine.

WiseRetail

The week in Indian retail, ecommerce and D2C — in one short email every Friday.